肿瘤相关性胰蛋白酶原-2在胰腺癌初筛中的意义  

Tumor-Associated Trypsinogen-2 in Prescreening Pancreatic Cancer

作　　者：王志红[1] 曹建彪 郭汉斌 崔婷婷[3] 杜囚鹏[3] 

机构地区：[1]北京军区总医院消化内科 [2]全军肝病治疗中心,北京100700 [3]山西医科大学第二临床医学院,太原030001

出　　处：《科学技术与工程》2011年第35期8855-8857,共3页Science Technology and Engineering

摘　　要：为研究胰腺癌患者血清肿瘤相关胰蛋白酶原-2在胰腺癌初筛中的意义,收集北京军区总医院23例胰腺癌住院患者的治疗前血清标本和35例正常对照者(健康体检者)血清标本。采用酶联免疫吸附法检测血清胰蛋白酶原-2含量。结果血清胰蛋白酶原-2含量在正常对照组中位数为0.8μg/L,四分位间距0.6～1.2μg/L;胰腺癌患者中位数为13.8μg/L,四分位间距2.3～60.7μg/L。胰腺癌组和正常对照组血清胰蛋白酶原-2水平有统计学差异(P<0.01)。以1.85μg/L为临界值作为诊断胰腺癌界定值的敏感度为91.4%,特异度为95.7%。证明血清胰蛋白酶原-2检测可作为胰腺癌的一种初筛试验。To study the role of serum Tumor-Associated Trypsinogen-2（TAT-2）in prescreening pancreatic canre,serum samples were collected from 23 patients who was diagnosed with pancreatic cancer at General Hospital of Beijing Military Region,serum samples from 35 healthy volunteers were used as control.Enzyme-linked immunosorbent assay was used to semiquantitatively determine serum TAT-2 level. It is resulted that median levels of serum TAT-2 was 0.8 μg/L（interquartile range,0.6～1.2 μg/L） and 13.8 μg/L（IQR,2.3～60.7 μg/L）（P0.01）.At a cut-off 1.85 μg/L,the diagnostic sensitivity and specificity for pancreatic cancer were 91.4% and 95.7%,respectively.It is conclused that serum TAT-2 can be used for prescreening pancreatic cancer with a favorable sensitivity and specificity.

关 键 词：胰腺癌 血清胰蛋白酶原-2 诊断 

分 类 号：R576[医药卫生—消化系统]